CANbridge Appoints Acting CMO
This article was originally published in Scrip
CANbridge Life Sciences, a company developing Western drug candidates in North Asia and China, has appointed Mark A. Goldberg acting chief medical officer (CMO) – effective immediately. Previously Goldberg was executive vice-president of medical and regulatory strategy at Synageva BioPharma Corp. Prior to this he was senior vice-president of clinical development and global therapeutic group head, oncology and personalized genetic health at Genzyme Corp.
You may also be interested in...
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.